Study of HLX37 with chemotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HLX37 combined with chemotherapy for people with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced (stage IIIB/IV) non-small cell lung cancer that has not been treated with systemic therapy before.
- Your cancer does not have certain genetic changes (like EGFR or ALK) that would require targeted treatment.
- You have at least one measurable tumor that has not been previously treated with radiation.
- You have not had major surgery or radiation within the past month.
- You have not taken any cancer immunotherapy within the past year.
- You are physically able to care for yourself (ECOG 0-1) and have a life expectancy of at least 3 months.
- You are willing to provide a tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new combination of drugs (HLX07, serplulimab, and chemotherapy) for people with advanced squamous non-small cell lung cancer that hasn't been treated before. The goal is to see if this combo works better than the current standard treatments.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.